Fasting hepatic de novo lipogenesis is not reliably assessed using circulating fatty acid markers.
Adult
Biomarkers
/ blood
Chromatography, Gas
/ methods
Deuterium
Deuterium Oxide
Diet
Fasting
Fatty Acids
/ blood
Female
Humans
Lipogenesis
Lipoproteins, VLDL
/ metabolism
Liver
/ metabolism
Male
Middle Aged
Nutrition Assessment
Palmitates
/ metabolism
Reproducibility of Results
Triglycerides
/ metabolism
Journal
The American journal of clinical nutrition
ISSN: 1938-3207
Titre abrégé: Am J Clin Nutr
Pays: United States
ID NLM: 0376027
Informations de publication
Date de publication:
01 02 2019
01 02 2019
Historique:
received:
09
08
2018
accepted:
03
10
2018
pubmed:
6
2
2019
medline:
23
10
2019
entrez:
6
2
2019
Statut:
ppublish
Résumé
Observational studies often infer hepatic de novo lipogenesis (DNL) by measuring circulating fatty acid (FA) markers; however, it remains to be elucidated whether these markers accurately reflect hepatic DNL. We investigated associations between fasting hepatic DNL and proposed FA markers of DNL in subjects consuming their habitual diet. Fasting hepatic DNL was assessed using 2H2O (deuterated water) in 149 nondiabetic men and women and measuring the synthesis of very low-density lipoprotein triglyceride (VLDL-TG) palmitate. FA markers of blood lipid fractions were determined by gas chromatography. Neither the lipogenic index (16:0/18:2n-6) nor the SCD index (16:1n-7/16:0) in VLDL-TG was associated with isotopically assessed DNL (r = 0.13, P = 0.1 and r = -0.08, P = 0.35, respectively). The relative abundances (mol%) of 14:0, 16:0, and 18:0 in VLDL-TG were weakly (r ≤ 0.35) associated with DNL, whereas the abundances of 16:1n-7, 18:1n-7, and 18:1n-9 were not associated. When the cohort was split by median DNL, only the abundances of 14:0 and 18:0 in VLDL-TG could discriminate between subjects having high (11.5%) and low (3.8%) fasting hepatic DNL. Based on a subgroup, FA markers in total plasma TG, plasma cholesteryl esters, plasma phospholipids, and red blood cell phospholipids were generally not associated with DNL. The usefulness of circulating FAs as markers of hepatic DNL in healthy individuals consuming their habitual diet is limited due to their inability to discriminate clearly between individuals with low and high fasting hepatic DNL.
Sections du résumé
Background
Observational studies often infer hepatic de novo lipogenesis (DNL) by measuring circulating fatty acid (FA) markers; however, it remains to be elucidated whether these markers accurately reflect hepatic DNL.
Objectives
We investigated associations between fasting hepatic DNL and proposed FA markers of DNL in subjects consuming their habitual diet.
Methods
Fasting hepatic DNL was assessed using 2H2O (deuterated water) in 149 nondiabetic men and women and measuring the synthesis of very low-density lipoprotein triglyceride (VLDL-TG) palmitate. FA markers of blood lipid fractions were determined by gas chromatography.
Results
Neither the lipogenic index (16:0/18:2n-6) nor the SCD index (16:1n-7/16:0) in VLDL-TG was associated with isotopically assessed DNL (r = 0.13, P = 0.1 and r = -0.08, P = 0.35, respectively). The relative abundances (mol%) of 14:0, 16:0, and 18:0 in VLDL-TG were weakly (r ≤ 0.35) associated with DNL, whereas the abundances of 16:1n-7, 18:1n-7, and 18:1n-9 were not associated. When the cohort was split by median DNL, only the abundances of 14:0 and 18:0 in VLDL-TG could discriminate between subjects having high (11.5%) and low (3.8%) fasting hepatic DNL. Based on a subgroup, FA markers in total plasma TG, plasma cholesteryl esters, plasma phospholipids, and red blood cell phospholipids were generally not associated with DNL.
Conclusions
The usefulness of circulating FAs as markers of hepatic DNL in healthy individuals consuming their habitual diet is limited due to their inability to discriminate clearly between individuals with low and high fasting hepatic DNL.
Identifiants
pubmed: 30721918
pii: S0002-9165(22)03118-5
doi: 10.1093/ajcn/nqy304
pmc: PMC6367991
doi:
Substances chimiques
Biomarkers
0
Fatty Acids
0
Lipoproteins, VLDL
0
Palmitates
0
Triglycerides
0
very low density lipoprotein triglyceride
0
Deuterium
AR09D82C7G
Deuterium Oxide
J65BV539M3
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Validation Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
260-268Subventions
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/N005600/1
Pays : United Kingdom
Organisme : British Heart Foundation
ID : PG/09/003
Pays : United Kingdom
Organisme : British Heart Foundation
ID : FS/11/18/28633
Pays : United Kingdom
Organisme : British Heart Foundation
ID : FS/15/56/31645
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/N015665/1
Pays : United Kingdom
Références
Diabetes. 2002 Sep;51(9):2684-90
pubmed: 12196459
Am J Clin Nutr. 2013 Aug;98(2):319-26
pubmed: 23803879
Diabetes. 2014 Nov;63(11):3785-97
pubmed: 24947352
Am J Physiol Endocrinol Metab. 2009 Jan;296(1):E64-71
pubmed: 18940935
Am J Clin Nutr. 2015 Jan;101(1):153-63
pubmed: 25527759
J Clin Invest. 2009 Feb;119(2):315-22
pubmed: 19164855
Diabetes. 2007 Oct;56(10):2433-41
pubmed: 17601988
J Clin Endocrinol Metab. 2015 Dec;100(12):4425-33
pubmed: 26414963
J Clin Invest. 1999 Oct;104(8):1087-96
pubmed: 10525047
Biochim Biophys Acta. 1977 Nov 1;470(3):465-74
pubmed: 921963
J Lipid Res. 2000 Apr;41(4):595-604
pubmed: 10744780
J Am Heart Assoc. 2015 Oct 02;4(10):e002258
pubmed: 26432801
J Lipid Res. 2003 Nov;44(11):2065-72
pubmed: 12923230
J Lipid Res. 1998 Jun;39(6):1280-6
pubmed: 9643360
Prog Lipid Res. 2008 Sep;47(5):348-80
pubmed: 18435934
Annu Rev Nutr. 1996;16:523-57
pubmed: 8839937
J Nutr. 2006 Mar;136(3):565-9
pubmed: 16484525
PLoS One. 2014 Nov 21;9(11):e113605
pubmed: 25415333
J Nutr. 2014 Jan;144(1):33-41
pubmed: 24225449
Eur J Clin Nutr. 2017 Aug;71(8):973-979
pubmed: 28294174
J Lipid Res. 1997 Aug;38(8):1571-82
pubmed: 9300779
Biochem J. 1990 Nov 1;271(3):761-6
pubmed: 2244877
Clin Chim Acta. 2002 Jul;321(1-2):63-7
pubmed: 12031594
J Lipid Res. 2003 Apr;44(4):846-53
pubmed: 12562844
Diabetologia. 2009 Aug;52(8):1628-37
pubmed: 19536518
Hum Immunol. 2017 Mar;78(3):242-251
pubmed: 28111166
Gastroenterology. 2014 Mar;146(3):726-35
pubmed: 24316260
J Clin Invest. 1963 May;42:675-85
pubmed: 13944427
J Hum Hypertens. 2010 May;24(5):312-9
pubmed: 19657359
J Clin Endocrinol Metab. 2015 Aug;100(8):E1125-32
pubmed: 26043229
Am J Clin Nutr. 2015 Jan;101(1):34-43
pubmed: 25527748
Proc Natl Acad Sci U S A. 1993 Mar 1;90(5):2069-73
pubmed: 8446630
Diabetes. 2016 Jul;65(7):1858-67
pubmed: 27207513
J Clin Endocrinol Metab. 2012 Dec;97(12):E2288-92
pubmed: 23015656
Am J Clin Nutr. 2011 Aug;94(2):431-8
pubmed: 21697077
Br J Nutr. 2011 Mar;105(6):857-65
pubmed: 21251339
J Clin Invest. 1996 May 1;97(9):2081-91
pubmed: 8621798
PLoS One. 2015 May 18;10(5):e0127368
pubmed: 25984792
Atherosclerosis. 1987 Jul;66(1-2):11-8
pubmed: 3632742
Clin Chem. 2009 Dec;55(12):2113-20
pubmed: 19850634
Diabetes. 2007 Jan;56(1):168-76
pubmed: 17192479
J Clin Invest. 2005 May;115(5):1343-51
pubmed: 15864352
Am J Clin Nutr. 2008 Apr;87(4):817-23
pubmed: 18400702
Clin Gastroenterol Hepatol. 2018 Dec;16(12):1983-1991.e3
pubmed: 29705265
Diabetes Metab. 2003 Nov;29(5):478-85
pubmed: 14631324
J Biol Chem. 1960 Sep;235:2579-83
pubmed: 14421317